Managing blood thinners around central line placement in cancer patients
Part of Cancer clinical trials.
This study tests a plan for how cancer patients taking blood thinners (called DOACs) should handle their medication before and after getting a central line (a special IV tube placed in a large vein for treatments). The goal is to find a safe way to prepare for the procedure without increasing the risk of bleeding or blood clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer and are taking a blood thinner (DOAC) for a blood clot or an irregular heartbeat (atrial fibrillation).
- Your cancer is active, meaning it was recently diagnosed, has spread, or you've had treatment in the last 6 months.
- You are scheduled to get a tunneled or port central line placed under X-ray guidance.
- You are willing to follow the study's plan for your blood thinner before and after the procedure.
- You do not have severely reduced kidney function (your doctor will check with a blood test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the safety of managing blood thinners (like apixaban or warfarin) around the time of cancer surgery or procedures. It aims to help doctors understand how to best handle these medications to reduce risks.
This trial tests whether continuing a lower dose of blood thinners can prevent another blood clot in cancer patients who have had a clot in an arm or chest catheter. It may help find a safer way to prevent future clots.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This trial tests whether a daily pill called edoxaban can prevent blood clots that sometimes form around a central venous catheter in people with cancer. If it works, it could lower the risk of a dangerous clot without major side effects.
This trial tests different ways to take the blood thinner apixaban to prevent blood clots in people with cancer who are starting or switching their cancer treatment. It aims to find the best dose for safety and effectiveness.
This study looks at how well blood thinners work in people with cancer and a recent blood clot. It measures the risk of bleeding by checking certain blood clotting factors.
Hear when a new Anticoagulant-induced Bleeding trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.